SCHEMBL360829

SCHEMBL360829

O=C(O)C1[CH]CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20295697 1.00
SCHEMBL20295933 1.00
SCHEMBL1864577 0.92
SCHEMBL1868510 0.92
SCHEMBL1864575 0.92
SCHEMBL5966226 0.90 POLB (0.36)
SCHEMBL5966260 0.86
SCHEMBL242415 0.80
SCHEMBL14398568 0.80
SCHEMBL28000893 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 844 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220194931-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2022-06-23 US claimed
CN-110582493-A Benzoxazole derivatives as immunomodulators 因赛特公司 2019-12-17 CN claimed
EP-3558985-A1 BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS Incyte Corporation (US) 2019-10-30 EP claimed
US-20180179197-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2018-06-28 US claimed
WO-2018119266-A1 BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS INCYTE CORPORATION (US) 2018-06-28 WO claimed
CN-101410414-A Synergistic compositions for treating HIV-1 ROCHE PALO ALTO LLC (CH) 2009-04-15 CN claimed
US-20080299132-A1 Synergistic compositions for treating HIV-1 ROCHE PALO ALTO LLC 2008-12-04 US claimed
EP-1981911-A2 SYNERGISTIC COMPOSITIONS FOR TREATING HIV F.HOFFMANN-LA ROCHE AG (CH) 2008-10-22 EP claimed
WO-2007085567-A2 SYNERGISTIC COMPOSITIONS FOR TREATING HIV F. HOFFMANN-LA ROCHE AG (CH) 2007-08-02 WO claimed
US-20060025345-A1 Substituted ethane-1,2-diamines for the treatment of Alzheimer's disease BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-02-02 US claimed
WO-2005113582-A1 SUBSTITUTED ETHANE-1,2-DIAMINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-12-01 WO claimed
US-20020037872-A1 N6 heterocyclic 5' modified adenosine derivatives CV THERAPEUTICS, INC. 2002-03-28 US claimed
US-6258793-B1 MODIFYING CARDIAC ACTIVITY, MODIFYING ADIPOCYTE FUNCTION, TREATING CENTRAL NERVOUS SYSTEM DISORDERS, AND TREATING DIABETIC DISORDERS AND OBESITY IN MAMMALS CV THERAPEUTICS, INC. 2001-07-10 US claimed
WO-2001040245-A1 N6 HETEROCYCLIC 5' MODIFIED ADENOSINE DERIVATIVES CV THERAPEUTICS, INC. (US) 2001-06-07 WO claimed
WO-2001040244-A1 N6 HETEROCYCLIC 5' MODIFIED ADENOSINE DERIVATIVES CV THERAPEUTICS, INC. (US) 2001-06-07 WO claimed
US-12043601-B2 N-substituted-1H-1,2,4-triazole-3-carboxamides, analogues thereof, and methods of treatment using same THE REGENTS OF THE UNIVERSITY OF COLORADO (US) 2024-07-23 US disclosed
WO-2024151969-A1 POTASSIUM CHANNEL BLOCKERS OR DERIVATIVES THEREOF FOR PREVENTING, ALLEVIATING, AND/OR TREATING MORBIDITY AND MORTALITY INDUCED BY PATHOGENS OR OTHER INDUCERS OF IMMUNE EXHAUSTION AND/OR EXCESS IMMUNE ACTIVATION UNIVERSITY OF ROCHESTER (US) 2024-07-18 WO disclosed
EP-0313081-A2 2-Oxa-isocephem compounds, compositions containing the same and processes for preparing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-04-26 EP disclosed
US-4151268-A ASSAYING FOR 5-SUBSTITUTED-1,3-UNSUBSTITUTED BARBITURIC ACIDS BY COMPLEXING WITH GAMMA GLOBULIN FRACTION PROTEINS HOFFMANN-LA ROCHE INC. (US) 1979-04-24 US disclosed
US-4107157-A Barbituric acid antigens and antibodies specific therefor HOFFMANN-LA ROCHE INC. (US) 1978-08-15 US disclosed